Given our recent discovery of somatic mutations in autism spectrum disorder (ASD)/intellectual disability (ID) genes in postmortem aged Alzheimer's disease brains correlating with increasing tauopathy, it is important to decipher if tauopathy is underlying brain imaging results of atrophy in ASD/ID children. We concentrated on activity-dependent neuroprotective protein (ADNP), a prevalent autism gene. The unique availability of multiple postmortem brain sections of a 7-year-old male, heterozygous for ADNP de novo mutation c.2244Adup/p.His559Glnfs*3 allowed exploration of tauopathy, reflecting on a general unexplored mechanism. The tested subject exhibited autism, fine motor delays, severe intellectual disability and seizures. The patient died after multiple organ failure following liver transplantation. To compare to other ADNP syndrome mutations, immortalized lymphoblastoid cell lines from three different patients (including ADNP p.Arg216*, p.Lys408Valfs*31, and p.Tyr719* heterozygous dominant mutations) and a control were subjected to RNA-seq. Immunohistochemistry, high-throughput gene expression profiles in numerous postmortem tissues followed. Comparisons to a control brain and to extensive datasets were used. Live cell imaging investigated Tau-microtubule interaction, protecting against tauopathy. Extensive child brain tauopathy paralleled by multiple gene expression changes was discovered. Tauopathy was explained by direct mutation effects on Tau-microtubule interaction and correction by the ADNP active snippet NAP. Significant pathway changes (empirical P value < 0.05) included over 100 genes encompassing neuroactive ligand-receptor and cytokine-cytokine receptor interaction, MAPK and calcium signaling, axon guidance and Wnt signaling pathways. Changes were also seen in steroid biosynthesis genes, suggesting sex differences. Selecting the most affected genes by the ADNP mutations for gene expression analysis, in multiple postmortem tissues, identified Tau (MAPT)-gene-related expression changes compared with extensive normal gene expression (RNA-seq) databases. ADNP showed relatively reduced expression in the ADNP syndrome cerebellum, which was also observed for 25 additional genes (representing >50% of the tested genes), including NLGN1, NLGN2, PAX6, SMARCA4, and SNAP25, converging on nervous system development and tauopathy. NAP provided protection against mutated ADNP disrupted Tau-microtubule association. In conclusion, tauopathy may explain brain-imaging findings in ADNP syndrome children and may provide a new direction for the development of tauopathy protecting drug candidates like NAP in ASD/ID.

BIOCEV Institute of Biotechnology CAS Průmyslová 595 252 50 Vestec Czech Republic

Clinical Department of Pathology and Cytology University Hospital Centre Zagreb Zagreb Croatia

Department of Medical Genetics University of Antwerp Antwerp Belgium

Department of Neurology Laboratory of Experimental Neurology AHEPA University Hospital Aristotle University of Thessaloniki Thessaloniki Greece

Department of Pediatrics Division of Pediatric Gastroenterology Hepatology and Nutrition University Hospital Centre Zagreb School of Medicine Zagreb Croatia

Elton Laboratory for Neuroendocrinology Department of Human Molecular Genetics and Biochemistry Sackler Faculty of Medicine Sagol School of Neuroscience and Adams Super Center for Brain Studies Tel Aviv University Tel Aviv Israel

The Blavatnik School of Computer Science Tel Aviv University Tel Aviv Israel

Zobrazit více v PubMed

Bassan M, et al. Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide. J. Neurochem. 1999;72:1283–1293. doi: 10.1046/j.1471-4159.1999.0721283.x. PubMed DOI

Zamostiano R, et al. Cloning and characterization of the human activity-dependent neuroprotective protein. J. Biol. Chem. 2001;276:708–714. doi: 10.1074/jbc.M007416200. PubMed DOI

Helsmoortel C, et al. A SWI/SNF-related autism syndrome caused by de novo mutations in ADNP. Nat. Genet. 2014;46:380–384. doi: 10.1038/ng.2899. PubMed DOI PMC

Deciphering Developmental Disorders S. Prevalence and architecture of de novo mutations in developmental disorders. Nature. 2017;542:433–438. doi: 10.1038/nature21062. PubMed DOI PMC

Stessman HA, et al. Targeted sequencing identifies 91 neurodevelopmental-disorder risk genes with autism and developmental-disability biases. Nat. Genet. 2017;49:515–526. doi: 10.1038/ng.3792. PubMed DOI PMC

Van Dijck A, et al. Clinical presentation of a complex neurodevelopmental disorder caused by mutations in ADNP. Biol. Psychiatry. 2019;85:287–297. doi: 10.1016/j.biopsych.2018.02.1173. PubMed DOI PMC

Amram N. et al. Sexual divergence in microtubule function: the novel intranasal microtubule targeting SKIP normalizes axonal transport and enhances memory. Mol. Psychiatry21, 1467–1476 (2016). PubMed

Merenlender-Wagner A, et al. Autophagy has a key role in the pathophysiology of schizophrenia. Mol. Psychiatry. 2015;20:126–132. doi: 10.1038/mp.2013.174. PubMed DOI PMC

Mandel S, Spivak-Pohis I, Gozes I. ADNP differential nucleus/cytoplasm localization in neurons suggests multiple roles in neuronal differentiation and maintenance. J. Mol. Neurosci. 2008;35:127–141. doi: 10.1007/s12031-007-9013-y. PubMed DOI

Hacohen-Kleiman G, et al. Activity-dependent neuroprotective protein deficiency models synaptic and developmental phenotypes of autism-like syndrome. J. Clin. Investig. 2018;128:4956–4969. doi: 10.1172/JCI98199. PubMed DOI PMC

Oz S, et al. The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins. Mol. Psychiatry. 2014;19:1115–1124. doi: 10.1038/mp.2014.97. PubMed DOI

Ivashko-Pachima Y, Sayas CL, Malishkevich A, Gozes I. ADNP/NAP dramatically increase microtubule end-binding protein-Tau interaction: a novel avenue for protection against tauopathy. Mol. Psychiatry. 2017;22:1335–1344. doi: 10.1038/mp.2016.255. PubMed DOI

Oz S, Ivashko-Pachima Y, Gozes I. The ADNP derived peptide, NAP modulates the tubulin pool: implication for neurotrophic and neuroprotective activities. PLoS ONE. 2012;7:e51458. doi: 10.1371/journal.pone.0051458. PubMed DOI PMC

Jouroukhin Y, et al. NAP (davunetide) modifies disease progression in a mouse model of severe neurodegeneration: protection against impairments in axonal transport. Neurobiol. Dis. 2013;56:79–94. doi: 10.1016/j.nbd.2013.04.012. PubMed DOI

Vulih-Shultzman I, et al. Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J. Pharmacol. Exp. Ther. 2007;323:438–449. doi: 10.1124/jpet.107.129551. PubMed DOI

Quraishe S, Cowan CM, Mudher A. NAP (davunetide) rescues neuronal dysfunction in a Drosophila model of tauopathy. Mol. Psychiatry. 2013;18:834–842. doi: 10.1038/mp.2013.32. PubMed DOI PMC

Ivashko-Pachima Y, Maor-Nof M, Gozes I. NAP (davunetide) preferential interaction with dynamic 3-repeat Tau explains differential protection in selected tauopathies. PLoS ONE. 2019;14:e0213666. doi: 10.1371/journal.pone.0213666. PubMed DOI PMC

Gozes I, et al. Premature primary tooth eruption in cognitive/motor-delayed ADNP-mutated children. Transl. Psychiatry. 2017;7:e1166. doi: 10.1038/tp.2017.128. PubMed DOI PMC

Ivashko-Pachima Y. et al. Discovery of autism/intellectual disability somatic mutations in Alzheimer’s brains: mutated ADNP cytoskeletal impairments and repair as a case study. Mol. Psychiatry (2019). (EPUB) PubMed PMC

Carithers LJ, et al. A novel approach to high-quality postmortem tissue procurement: the GTEx project. Biopreserv. Biobank. 2015;13:311–319. doi: 10.1089/bio.2015.0032. PubMed DOI PMC

Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA. 2005;102:15545–15550. doi: 10.1073/pnas.0506580102. PubMed DOI PMC

Hait TA, et al. The EXPANDER integrated platform for transcriptome analysis. J. Mol. Biol. 2019;431:2398–2406. doi: 10.1016/j.jmb.2019.05.013. PubMed DOI

Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28:27–30. doi: 10.1093/nar/28.1.27. PubMed DOI PMC

Liberzon A, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1:417–425. doi: 10.1016/j.cels.2015.12.004. PubMed DOI PMC

Escher U, et al. Anti-inflammatory effects of the octapeptide NAP in human microbiota-associated mice suffering from Subacute Ileitis. Eur. J. Microbiol. Immunol. 2018;8:34–40. doi: 10.1556/1886.2018.00006. PubMed DOI PMC

Heimesaat MM, Giladi E, Kuhl AA, Bereswill S, Gozes I. The octapetide NAP alleviates intestinal and extra-intestinal anti-inflammatory sequelae of acute experimental colitis. Peptides. 2018;101:1–9. doi: 10.1016/j.peptides.2017.12.023. PubMed DOI

Mandel S, Rechavi G, Gozes I. Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis. Dev. Biol. 2007;303:814–824. doi: 10.1016/j.ydbio.2006.11.039. PubMed DOI

Yeung J, Ha TJ, Swanson DJ, Goldowitz D. A novel and multivalent role of Pax6 in cerebellar development. J. Neurosci. 2016;36:9057–9069. doi: 10.1523/JNEUROSCI.4385-15.2016. PubMed DOI PMC

Sragovich S, et al. The autism/neuroprotection-linked ADNP/NAP regulate the excitatory glutamatergic synapse. Transl. Psychiatry. 2019;9:2. doi: 10.1038/s41398-018-0357-6. PubMed DOI PMC

Glaser T, et al. PAX6 gene dosage effect in a family with congenital cataracts, aniridia, anophthalmia and central nervous system defects. Nat. Genet. 1994;7:463–471. doi: 10.1038/ng0894-463. PubMed DOI

Heins N, et al. Glial cells generate neurons: the role of the transcription factor Pax6. Nat. Neurosci. 2002;5:308–315. doi: 10.1038/nn828. PubMed DOI

Mandel S, Gozes I. Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. J. Biol. Chem. 2007;282:34448–34456. doi: 10.1074/jbc.M704756200. PubMed DOI

Hacohen-Kleiman G, et al. Atypical auditory brainstem response and protein expression aberrations related to ASD and hearing loss in the adnp haploinsufficient mouse brain. Neurochem. Res. 2019;44:1494–1507. doi: 10.1007/s11064-019-02723-6. PubMed DOI

Muenke M, et al. A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome. Nat. Genet. 1994;8:269–274. doi: 10.1038/ng1194-269. PubMed DOI

Villanueva C, de Roux N. FGFR1 mutations in Kallmann syndrome. Front. Horm. Res. 2010;39:51–61. doi: 10.1159/000312693. PubMed DOI

Trokovic N, Trokovic R, Mai P, Partanen J. Fgfr1 regulates patterning of the pharyngeal region. Genes Dev. 2003;17:141–153. doi: 10.1101/gad.250703. PubMed DOI PMC

Tai C, et al. Tau reduction prevents key features of autism in mouse models. Neuorn. 2020;106:421–437. doi: 10.1016/j.neuron.2020.01.038. PubMed DOI PMC

La Joie R. et al. Prospective longitudinal atrophy in Alzheimer’s disease correlates with the intensity and topography of baseline tau-PET. Sci. Transl. Med.12, eaau5732 (2020). PubMed PMC

Tomasoni R, et al. SNAP-25 regulates spine formation through postsynaptic binding to p140Cap. Nat. Commun. 2013;4:2136. doi: 10.1038/ncomms3136. PubMed DOI

Malishkevich A, Leyk J, Goldbaum O, Richter-Landsberg C, Gozes I. ADNP/ADNP2 expression in oligodendrocytes: implication for myelin-related neurodevelopment. J. Mol. Neurosci. 2015;57:304–313. doi: 10.1007/s12031-015-0640-4. PubMed DOI

Malishkevich A, et al. Activity-dependent neuroprotective protein (ADNP) exhibits striking sexual dichotomy impacting on autistic and Alzheimer’s pathologies. Transl. Psychiatry. 2015;5:e501. doi: 10.1038/tp.2014.138. PubMed DOI PMC

Pinhasov A, et al. Activity-dependent neuroprotective protein: a novel gene essential for brain formation. Dev. Brain Res. 2003;144:83–90. doi: 10.1016/S0165-3806(03)00162-7. PubMed DOI

Vaisburd S, Shemer Z, Yeheskel A, Giladi E, Gozes I. Risperidone and NAP protect cognition and normalize gene expression in a schizophrenia mouse model. Sci. Rep. 2015;5:16300. doi: 10.1038/srep16300. PubMed DOI PMC

Editorial: A Child with ADNP Syndrome: A Case Study of Symptoms, Diagnostic Process and Innovative Behavioral Intervention Modes